check_circleStudy Completed

Urinary Tract Infections

Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens

Trial purpose

Researchers want to find out if a drug called Cipro® XR (ciprofloxacin extended-release) can help people with a complicated urinary tract infection caused by a kind of bacteria called Pseudomonas aeruginosa. The study doctor will give Cipro XR to some people to see if it is safe and works to treat complicated urinary tract infections caused by Pseudomonas aeruginosa. The study doctor will also gather information about using Cipro XR to treat complicated urinary tract infections caused by other bacteria. About 500 people with complicated urinary tract infections who are 18 years old and older will join this study. Cipro XR is approved by the U.S. Food and Drug Administration (FDA) for the treatment of complicated urinary tract infections and acute uncomplicated pyelonephritis (inflammation of the kidney). The dose of Cipro XR used in this study (1000 mg a day for 7 to 14 days), has been shown to be safe and effective. This study is being done to gather more information on using this dose of Cipro XR for complicated urinary tract infections caused by Pseudomonas aeruginosa, as well as by other bacteria.

Key Participants Requirements

Sex

Both

Age

18 Years

Trial summary

Enrollment Goal
500
Trial Dates
May 2004 - September 2005
Phase
Phase 4
Could I Receive a placebo
No
Products
Cipro XR (Ciprofloxacin, BAYQ3939)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Center for Urological ResearchLa Mesa, 91942-3058, United States
Completed
Urological Physicians of San DiegoSan Diego, 92103, United States
Completed
ACT - Albuquerque Clinical TrialsAlbuquerque, 87102, United States
Completed
Florida Foundation for Healthcare ResearchOcala, 34474, United States
Completed
Madigan Army Medical CenterTacoma, 98431-5000, United States
Completed
Urology Group of New MexicoAlbuquerque, 87109, United States
Completed
Alabama Research Center, LLCBirmingham, 35209, United States
Completed
Scottsdale Urologic & Reproductive SpecialistsScottsdale, 85258, United States
Completed
South Florida Urology CenterPembroke Pines, 33027, United States
Completed
Clinical Research SolutionsLas Vegas, 89109, United States
Completed
Rx for Life, Inc.Cudahy, 90201, United States
Completed
Iowa Clinic,PC/ Iowa UrololgyDes Moines, 50309, United States
Completed
Urology Specialists, PCWaterbury, 06708, United States
Completed
DiGiovanna Family Care CenterNorth Massapequa, 11758, United States
Completed
VA New Jersey Health Care SystemEast Orange, 07918, United States
Completed
Atlantic Urology Medical GroupLong Beach, 90806, United States
Completed
South Coast Urological Medical GroupLaguna Hills, 92653, United States
Completed
Urology San Antonio Research, PASan Antonio, 78229, United States
Completed
Urology of Indiana, LLCIndianapolis, 46202, United States
Completed
Nevada Urology AssociatesReno, 89511-2069, United States
Completed
Medical Affiliated Research Center, Inc.Huntsville, 35801, United States
Completed
Urology Associates of Central CaliforniaFresno, 93720-0153, United States
Completed
Parkway Medical CenterBirmingham, 35206, United States
Completed
Wyoming Research Foundation, Inc.Cheyenne, 82001, United States
Completed
Seton Health SystemTroy, 12180-1695, United States
Completed
VA Medical Center-Jefferson Barracks DivisionSt. Louis, 63125, United States
Completed
Southeast Urology NetworkMemphis, 38119, United States
Completed
McGuire Veterans Affairs Medical CenterRichmond, 23249-0002, United States
Completed
Health Care Partners Medical GroupTorrance, 90503, United States
Completed
Bay State Clinical Trials, IncWatertown, 02472, United States
Completed
Thomas Jefferson University HospitalsPhiladelphia, 19107-5096, United States
Completed
Healthcare Partners Medical GroupLos Angeles, 90015, United States
Completed
Oregon Urology SpecialistsEugene, 97401, United States
Completed
University of Iowa Hospitals & ClinicsIowa City, 52242-1089, United States
Completed
Urology Associates, PCManhasset, 11030-1961, United States

Primary Outcome

  • To evaluate safety and efficacy of ciprofloxacin XR for treatment of subjects with complicated urinary tract infections caused by P. aeruginosa and other urinary pathogens.
    date_rangeTime Frame:
    28-42 days after therapy
    enhanced_encryption
    Safety Issue:
    yes

Secondary Outcome

  • Clinical response
    date_rangeTime Frame:
    TOC visit
    enhanced_encryption
    Safety Issue:
    yes
  • Clinical response post- treatment
    date_rangeTime Frame:
    28-42 days after therapy
    enhanced_encryption
    Safety Issue:
    yes
  • Adverse Event collection
    date_rangeTime Frame:
    Until end of study
    enhanced_encryption
    Safety Issue:
    yes

Trial design

Prospective, open-label, noncomparative, multicenter study to evaluate the efficacy and safety of ciprofloxacin extended release (Cipro XR) 1000 mg tablets given once daily for 7 to 14 days in the treatment of patients 18 years or older with complicated urinary tract infections caused by Pseudomonas aeruginosa and other common uropathogens
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
Randomized
Blinding
Open Label
Assignment
Parallel Assignment
Trial Arms
N/A